MFG
CTKB icon

Mendota Financial Group’s Cytek Biosciences CTKB Stock Holding History

Mendota Financial Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13
Closed -$73 – 563
2024
Q3 		$73 Buy
+13
New +$74 ﹤0.01% 1041

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mendota Financial Group's CTKB Position: Q4 2024 in Review

Mendota Financial Group sold out of Cytek Biosciences (CTKB) in Q4 2024, closing a stake of 13 shares — an estimated $73 sold.

Mendota Financial Group first reported a position in CTKB in Q3 2024 and held it in 1 quarter. The position peaked at $73 in Q3 2024. 152 funds tracked by Wall St. Rank hold CTKB as of Q4 2024.

  • Mendota Financial Group reported no remaining Cytek Biosciences position as of Q4 2024 after selling out during the quarter.
  • Mendota Financial Group sold 13 Cytek Biosciences shares in Q4 2024, an estimated $73.
  • Mendota Financial Group first reported a position in Cytek Biosciences in Q3 2024 and held it in 1 quarter.
  • Mendota Financial Group's Cytek Biosciences position peaked at $73 in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2024.

Based on Mendota Financial Group's 13F filing for Q4 2024, filed 14 Jan 2025.